Oncology & Cancer

Cost burden of disease progression high in multiple myeloma

(HealthDay)—The economic burden of disease progression is considerable among multiple myeloma (MM) patients receiving drug therapy across all lines of therapy (LOTs), according to a study published online Aug. 7 in Leukemia ...

Medications

Critical heart drug too pricey for some Medicare patients

An effective drug to treat chronic heart failure may cost too much for senior citizens with a standard Medicare Part D drug plan, said a study co-authored by a John A. Burns School of Medicine (JABSOM) researcher at the University ...

page 33 from 40